<DOC>
	<DOCNO>NCT01683474</DOCNO>
	<brief_summary>1. objective - Evaluate performance Venus MedTech aortic valve prosthesis intervention femoral artery - Evaluate safety clinical benefit percutaneous implantation Venue MedTech aortic valve prosthesis . - Continuous observe 12 month safety efficacy . 2 . Approximately 80 patient present native aortic valve stenosis necessitate valve replacement consider unsuitable Surgical Valve Replacement , high surgical risk , attest surgeon cardiologist recruit study . 3 . Safety performance evaluate discharge 30 day post procedure . Valve safety , performance placement follow 6 12 month post-procedure .</brief_summary>
	<brief_title>Safety Performance TAVI Venus MedTech Aortic Valve Prosthesis</brief_title>
	<detailed_description>A prospective OPC study evaluate performance long-term safety effectiveness Venus-A aortic valve .</detailed_description>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Senile degenerative aortic valve stenosis echocardiography derive criterion : mean gradient ≥ 40 mm Hg , jet velocity ≥ 4.0 m/s , aortic valve area ( AVA ) &lt; 0.8 cm2 ( AVA index ＜ 0.5 cm2/m2 ) Symptomatic due aortic valve stenosis demonstrate NYHA Functional Class ≥ II The subject subject 's legal representative inform nature study , agree provision provide write informed consent approve Institutional Review Board respective clinical site . The subject agree comply followup evaluation evaluate least one cardiologist two cardiovascular surgeon , agree medical factor preclude operation suitable surgery ( probability death serious , irreversible morbidity exceed 50 % ) STS score ≥ 10 % Patient refuse aortic valve replacement surgery . Evidence acute myocardial infarction ≤ 1 month intend treatment [ define : Q wave MI , nonQ wave MI total CK elevation CKMB ≥ twice normal presence MB elevation and/or troponin level elevation ( WHO definition ) ] . Aortic valve congenital unicuspid congenital bicuspid valve , noncalcified . Mixed aortic valve disease ( aortic stenosis aortic regurgitation predominant aortic regurgitation &gt; 3+ ) . Any therapeutic invasive cardiac procedure result permanent implant perform within 30 day （6 month DES implant） Implanted heart valve prosthesis , prosthetic valve ring , severe mitral valve ring calcification ( MAC ) , severe（ &gt; 3＋）mitral valve insufficiency , Gorelin symptom Blood dyscrasia leukopenia ( WBC &lt; 3×109/L ) , acute anemia ( Hgb &lt; 90 g/L ) , thrombocytopenia ( PLT &lt; 50×109/L ) , bleed diathesis , history coagulopathy . Untreated clinically significant coronary artery disease require revascularization Hemodynamic instability require inotropic therapy mechanical hemodynamic support device Need emergency surgery reason Hypertrophic cardiomyopathy without obstruction ( HOCM ) Severe ventricular dysfunction LVEF &lt; 20 % Echocardiographic evidence intracardiac mass , thrombus vegetation Active peptic ulcer upper gastrointestinal bleeding within prior 3 month A know hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , Nitinol , sensitivity contrast medium adequately premedicated . Native aortic annulus size &lt; 20 mm &gt; 29 mm measure echocardiogram . Cerebrovascular Accident ( CVA ) within 6 month , include TIA . Renal insufficiency ( creatinine &gt; 3.0 mg/dL ) and/or end stage renal disease require chronic dialysis . Life expectancy &lt; 12 month Significant abdominal thoracic aorta disease , include aneurysm ( define maximal luminal diameter 5cm great ) , mark tortuosity ( hyperacute bend ) , aortic arch atheroma ( especially thick [ &gt; 5 mm ] , protrude ulcerated ) , narrow abdominal aorta ( especially calcification surface irregularity ) , severe `` unfolding '' tortuosity thoracic aorta Iliofemoral vessel characteristic would preclude safe placement 16F 18F introducer sheath severe obstructive calcification , severe tortuosity vessel size diameter ＜ 7 mm . Currently participate investigational drug another device study . Active bacterial endocarditis active infection . Bulky calcify aortic valve leaflet close proximity coronary ostia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>aortic valve stenosis</keyword>
	<keyword>Calcification</keyword>
	<keyword>TAVI</keyword>
	<keyword>aortic valve Prosthesis</keyword>
</DOC>